AU · rank #17 · 2026-09-07
CORT
NASDAQ · $11.94B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.714 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$1.20 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.159 |
| Analyst upside Consensus target $141.00 | +26.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +28.81% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $126.38 |
| Market cap (USD) | $11.94B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Corcept Therapeutics is a commercial-stage biopharmaceutical company developing and commercializing cortisol-modulating therapies for Cushing's syndrome and oncologic indications.
Rationale
The quant model's bullish analyst signals are strongly validated by a 535% Q2 earnings surprise, 100% upward revision agreement, and management raising FY2026 revenue guidance to $1.1–$1.2 billion.
Material risks
- 1Extreme revenue concentration from sole reliance on the Korlym franchise and the early-stage Lifyorli launch, exposing the company to competitive cortisol modulators.
- 2Clinical pipeline failure of ongoing oncology and hypercortisolism programs, which would limit long-term diversification beyond the dual commercial franchise.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.